Literature DB >> 11485916

Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.

G A Gmyrek1, M Walburg, C P Webb, H M Yu, X You, E D Vaughan, G F Vande Woude, B S Knudsen.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) promotes the proliferation, differentiation, motility, and invasion of epithelial cells by binding to its cell surface receptor, the Met tyrosine kinase. In the prostate, Met is expressed predominantly by prostate epithelial cells (PrEC), whereas HGF/SF is synthesized by prostate stromal cells (PrSC). Met is also expressed in localized and metastatic prostate cancers. Our results show that PrECs in in vitro culture maintain expression of Met at a level comparable to DU145 cancer cell expression. HGF/SF secreted by PrSC stimulates tyrosine phosphorylation of the Met receptor. In normal PrEC, HGF/SF causes growth inhibition, sustained phosphorylation of mitogen-activated protein kinase, and increased CK18 expression consistent with cell differentiation. In contrast, HGF/SF significantly stimulates the proliferation of DU145 prostate cancer cells. HGF/SF in the conditioned medium of PrSC specifically induces migration of both normal and malignant prostate epithelial cells through MatriGel-coated Transwell filters. HGF/SF depletion reduces cell migration by approximately 50%. The response of PrEC is specific for HGF/SF since the other growth factors tested do not significantly affect growth or migration of PrECs. These results support the in vivo importance of the prostate stroma and specifically of HGF/SF as a unique stromal derived factor in the development and progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485916      PMCID: PMC1850543          DOI: 10.1016/S0002-9440(10)61729-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  76 in total

1.  Activating mutations for the met tyrosine kinase receptor in human cancer.

Authors:  M Jeffers; L Schmidt; N Nakaigawa; C P Webb; G Weirich; T Kishida; B Zbar; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma.

Authors:  J C Fanburg; A E Rosenberg; D L Weaver; K O Leslie; K G Mann; D J Taatjes; R P Tracy
Journal:  Am J Clin Pathol       Date:  1997-10       Impact factor: 2.493

3.  Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway.

Authors:  M Jeffers; G A Taylor; K M Weidner; S Omura; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

4.  Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma.

Authors:  P B Googe; K M McGinley; J F Fitzgibbon
Journal:  Am J Clin Pathol       Date:  1997-02       Impact factor: 2.493

5.  A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates.

Authors:  D Krill; M Shuman; M T Thompson; M J Becich; S C Strom
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

6.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

Review 7.  Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis.

Authors:  M Jeffers; S Rong; G F Vande Woude
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

8.  Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.

Authors:  M Jeffers; S Rong; M Anver; G F Vande Woude
Journal:  Oncogene       Date:  1996-08-15       Impact factor: 9.867

9.  Met and hepatocyte growth factor/scatter factor expression in human gliomas.

Authors:  S Koochekpour; M Jeffers; S Rulong; G Taylor; E Klineberg; E A Hudson; J H Resau; G F Vande Woude
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

10.  Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma.

Authors:  N Rahimi; E Tremblay; L McAdam; M Park; R Schwall; B Elliott
Journal:  Cell Growth Differ       Date:  1996-02
View more
  33 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE).

Authors:  Eric W Deutsch; Catherine A Ball; Jules J Berman; G Steven Bova; Alvis Brazma; Roger E Bumgarner; David Campbell; Helen C Causton; Jeffrey H Christiansen; Fabrice Daian; Delphine Dauga; Duncan R Davidson; Gregory Gimenez; Young Ah Goo; Sean Grimmond; Thorsten Henrich; Bernhard G Herrmann; Michael H Johnson; Martin Korb; Jason C Mills; Asa J Oudes; Helen E Parkinson; Laura E Pascal; Nicolas Pollet; John Quackenbush; Mirana Ramialison; Martin Ringwald; David Salgado; Susanna-Assunta Sansone; Gavin Sherlock; Christian J Stoeckert; Jason Swedlow; Ronald C Taylor; Laura Walashek; Anthony Warford; David G Wilkinson; Yi Zhou; Leonard I Zon; Alvin Y Liu; Lawrence D True
Journal:  Nat Biotechnol       Date:  2008-03       Impact factor: 54.908

3.  Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.

Authors:  Aaron P Putzke; Aviva P Ventura; Alexander M Bailey; Canan Akture; John Opoku-Ansah; Müge Celiktaş; Michael S Hwang; Douglas S Darling; Ilsa M Coleman; Peter S Nelson; Holly M Nguyen; Eva Corey; Muneesh Tewari; Colm Morrissey; Robert L Vessella; Beatrice S Knudsen
Journal:  Am J Pathol       Date:  2011-05-04       Impact factor: 4.307

4.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Authors:  Jared M Lucas; Cynthia Heinlein; Tom Kim; Susana A Hernandez; Muzdah S Malik; Lawrence D True; Colm Morrissey; Eva Corey; Bruce Montgomery; Elahe Mostaghel; Nigel Clegg; Ilsa Coleman; Christopher M Brown; Eric L Schneider; Charles Craik; Julian A Simon; Antonio Bedalov; Peter S Nelson
Journal:  Cancer Discov       Date:  2014-08-13       Impact factor: 39.397

5.  Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.

Authors:  W-Y Chen; Y-C Tsai; M K Siu; H-L Yeh; C-L Chen; J J Yin; J Huang; Y-N Liu
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

6.  Differences in phenotype and gene expression of prostate stromal cells from patients of varying ages and their influence on tumour formation by prostate epithelial cells.

Authors:  Yong-Chuan Wang; Sheng-Qiang Yu; Xiao-Hai Wang; Bang-Min Han; Fu-Jun Zhao; Guang-Hui Zhu; Yan Hong; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2011-06-06       Impact factor: 3.285

7.  Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.

Authors:  Geert J L H van Leenders; Wesley R Gage; Jessica L Hicks; Bianca van Balken; Tilly W Aalders; Jack A Schalken; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

8.  Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.

Authors:  Beatrice S Knudsen; Jared M Lucas; Ladan Fazli; Sarah Hawley; Seth Falcon; Ilsa M Coleman; Dan B Martin; Chang Xu; Lawrence D True; Martin E Gleave; Peter S Nelson; Gustavo E Ayala
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

9.  Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death.

Authors:  Mathew J Edick; Lia Tesfay; Laura E Lamb; Beatrice S Knudsen; Cindy K Miranti
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

10.  Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells.

Authors:  Heather M Bill; Beatrice Knudsen; Sheri L Moores; Senthil K Muthuswamy; Vikram R Rao; Joan S Brugge; Cindy K Miranti
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.